
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is a strong financial investment opportunity due to its impressive revenue and EBITDA growth projections for 2026 and 2027, as well as its unique position in the digital health market with its vertically integrated health intelligence platform and AI-driven recommendations. While there are potential risks associated with industry conditions and customer retention, management has shown strong cost management and a growing pipeline, which should lead to continued success in the enterprise market and overall company growth. Additionally, DarioHealth's recent announcement of a partnership with a hospital system further expands its potential for future revenue growth and innovative solutions in chronic care management.
Bears say
DarioHealth is a digital therapeutics company with a vertically integrated health intelligence platform, offering personalized interventions, hardware devices for physiological data generation, and AI. However, concerns arise from softer revenue performance and potential risks, such as competition. Recent expansions and partnerships show potential for revenue growth, but the company's focus on B2B2C solutions may limit its reach to consumers and lead to slower revenue growth. With the company still not reaching EBITDA breakeven and a high target price based on revenue estimates, the negative outlook stems from uncertainties about the company's ability to achieve sustainable profitability and concerns about its long-term growth potential.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares